ホーム › 頭頸部がん › テネシー › Nashville
Nashville、TNにおける頭頸部がんの臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、頭頸部がんに関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
被験者募集中第2/3相
- Site#0126, Nashville
- Site #0116, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
被験者募集中第1相
- Sarah Cannon and HCA Research Institute, Nashville
Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]
被験者募集中
- Barbara Murphy, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
被験者募集中
- Vanderbilt University Medical Center, Nashville
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- GSK Investigational Site, Nashville
High-Resolution PET-CT Imaging for Surgical Margin Visualization
被験者募集中
- Vanderbilt University Medical Center, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
- 他1件
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology, Nashville
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
被験者募集中第1/2相
- Vanderbilt-Ingram Cancer Center, Nashville
他の都市における頭頸部がんの試験
- Houston, TX30件の研究
- Boston, MA22件の研究
- New York City, NY21件の研究
- St. Louis, MO15件の研究
- Dallas, TX12件の研究
- Pittsburgh, PA11件の研究
- Los Angeles, CA10件の研究
- San Antonio, TX10件の研究
- Washington, DC10件の研究
- Baltimore, MD10件の研究
- Durham, NC10件の研究
- Chicago, IL10件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。